Clinical Science (2018) 132(4), 489–507; https://doi.org/10.1042/CS20180031

The published article contains several errors introduced during the production process.

  1. In the penultimate sentence of the Introduction, the web address, ClinicalTrials.gov incorrectly linked to a reference. The correct sentence is presented here:

    Furthermore, linagliptin is the first and so far only DPP-4 inhibitor to be evaluated in a randomized clinical trial designed to robustly assess renal outcomes: the ongoing Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA®; ClinicalTrials.gov: NCT01897532).

  2. In the captions to Figures 1 and 3, the reference citations attributed to statements of permission to reproduce were incorrect; the correct sources of the figures are presented here.

  • Figure 1 was reproduced from reference [18]: Shi, S., Koya, D. and Kanasaki, K. (2016) Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair 9, 1, https://doi.org/10.1186/s13069-016-0038-0

  • Figure 3 was reproduced from reference [107]: Zeisberg, M. and Zeisberg, E.M. (2015) Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int. 88, 429–431, https://doi.org/10.1038/ki.2015.175

    Corrected online 8 January 2019.

View Original Article
© 2019 The Author(s).
2019
This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).